MediView XR, Inc.
$34.4K 98 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Cycle Pharmaceuticals Inc
Cycle Pharmaceuticals Inc reported $34,382.44 across General Payments, Research, and Ownership to 1,022 physicians and teaching hospitals across 1,022 transactions.
- $34.4K Below-median payer
- All-tracks total
- 1,022 Above-median volume
- Transactions
- 1,022 Above-median reach
- Recipients
- −$54.6K
- General Payments vs PY2023
Cycle Pharmaceuticals Inc reported $34,382.44 across all CMS Open Payments tracks (General + Research + Ownership) to 1,022 physicians and teaching hospitals in Program Year 2024 - ranking #1444 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $34,382.44, averaging $33.64 per recipient.
How Cycle Pharmaceuticals Inc's $34.4K all-tracks total breaks down
Cycle Pharmaceuticals Inc's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
17/100
Total payments
F
10/100
Transaction volume
F
17/100
Physician reach
F
18/100
Payment type diversity
F
23/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer cycle-pharmaceuticals-inc Cycle Pharmaceuticals Inc
$34.4K · #1444/1,925 · 0.0% industry · PY2024
- TOT $34.4K
- RANK #1444
- SHARE 0.0%
- TXN 1,022
- RCP 1,022
- CAT 2
- GEN $34.4K
- ΔGEN −$54.6K
- TOP1 17.7%
- PY 2024
Volume peers
Nearest volume peer: MediView XR, Inc. ($34.4K)
Cycle Pharmaceuticals Inc sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Cycle Pharmaceuticals Inc's CMS-reported General Payments decreased by $54.6K (−61.4%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: CYCLE PHARMACEUTICALS INCPY2023: CYCLE PHARMACEUTICALS INCPY2024: Cycle Pharmaceuticals Inc. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $88,962.47
- PY2024
- $34,382.44
What the Data Shows for Cycle Pharmaceuticals Inc
The all-tracks total above combines three CMS reporting categories - General Payments, Research Payments, and Ownership/Investment interests - not one undifferentiated figure. For Cycle Pharmaceuticals Inc, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS publishes each Program Year's data roughly 12 months after the reporting period ends, so this reflects the most recently released cycle; see our methodology for how the tracks are standardized and compared across companies.
The 2-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Food and Beverage" at $17.9K, accounting for 52.2% of this company's General Payments and 1,012 transactions.
General Payment Breakdown by Type
Cycle Pharmaceuticals Inc made 2 types of general payments. "Food and Beverage" is the largest category at $17.9K, 52.2% of General Payments.
How Cycle Pharmaceuticals Inc divides its payments
Top payment categories by total reported dollar volume
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Food and Beverage | $17.9K | 1,012 | 52.2% |
| Compensation for Services Other Than Consulting | $16.4K | 10 | 47.8% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $11,553.60 (33.6%) of $34,382.44 in this company's General Payments records across 793 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Cycle Pharmaceuticals Inc
The five named recipients with the highest reported General Payments from this company
- 1
Jonathan Santoro
$6,090.51 across 2 reported transactions
- 2
Stephen Krieger
$1,400.00 across 1 reported transactions
- 3
Stephen Cannon
$1,400.00 across 1 reported transactions
- 4
Christopher Randolph
$1,399.93 across 3 reported transactions
- 5
Stephen Fritz
$1,263.16 across 3 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Cycle Pharmaceuticals Inc's spend rank (#1444 of 1,925, bottom 25% by spend) and concentration rank (#1,350 of 1,838, bottom 27% least concentrated) land at roughly the same percentile, an unusually proportionate case where payment size and payment concentration move together.
View all 12 companies in this HHI neighborhood as a list
- ZOLL Respicardia, Inc. : $325.9K total payments, HHI 435
- Vasorum USA Inc. : $12.3K total payments, HHI 435
- Hikma Pharmaceuticals USA : $501.2K total payments, HHI 435
- Butterfly Network, Inc. : $100.3K total payments, HHI 434
- Acera Surgical, Inc. : $623.5K total payments, HHI 432
- Sirtex Medical Inc : $2.5M total payments, HHI 432
- Cycle Pharmaceuticals Inc (this company) : $34.4K total payments, HHI 430
- Eli Lilly and Company : $8.0M total payments, HHI 429
- ASD Specialty Healthcare, LLC : $5.3K total payments, HHI 428
- Extremity Medical : $657.9K total payments, HHI 428
- 3-D Matrix, Inc. : $51.0K total payments, HHI 427
- Fisher Scientific Company L.L.C. : $185.9K total payments, HHI 424
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Cycle Pharmaceuticals Inc's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Cycle Pharmaceuticals Inc.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Cycle Pharmaceuticals Inc.
Showing 6 of 1,924 companies with CMS-reported payment data.
Olympus Winter & Ibe GmbH
$34.4K 14 recipients
Compare payment profiles
ZSFab, Inc.
$34.3K 107 recipients
Compare payment profiles
Dentsply Sirona Pty Limited
$34.5K 8 recipients
Compare payment profiles
Active Medical, LLC
$34.6K 179 recipients
Compare payment profiles
Captiox LLC
$34.7K 37 recipients
Compare payment profiles
Put this to use
Cycle Pharmaceuticals Inc ranks #1444 of 1,925 by all-tracks total payments, led by "Food and Beverage".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Food and Beverage" spend across every manufacturer, not just Cycle Pharmaceuticals Inc. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.